Novo Nordisk partners Emcure Pharma for weight loss medicine Poviztra in India

Pharma Pulse: FDA Expands Priority Voucher Program, as Oral Semaglutide Shows New Benefits and Cost Plus Drugs Adds Starjemza

This episode of Pharma Pulse discusses FDA’s growing National Priority Voucher initiative, fresh data on oral semaglutide’s cardiometabolic impact, and Mark Cuban’s latest drug addition that signals key shifts in innovation, access, and affordability across the pharmaceutical landscape.

Novo Nordisk, Emcure to Launch Weight-Loss Drug in India

Key Highlights Novo Nordisk partners with Emcure to market its Poviztra, a semaglutide-based weight-loss drug in India. The move follows Eli Lilly’s successful rollout of Mounjaro, signaling a rapidly growing market for obesity drugs. Shares of Emcure Pharma surged 6.5% after the announcement. Danish pharmaceutical major Novo Nordisk has joined forces with Emcure Pharmaceuticals to launch a new weight-loss drug in India, riding the momentum cre…

Novo Nordisk Partners with Emcure to Launch New Weight-Loss Drug Brand ‘Poviztra’ in India

Novo Nordisk has announced an exclusive partnership with Emcure Pharmaceuticals to distribute and market its new weight-loss drug brand, Poviztra, in India. The Danish pharmaceutical giant will introduce Poviztra as a 2.4 mg semaglutide injection, representing a separate brand of its globally successful treatment, Wegovy. This strategic collaboration aims to enhance accessibility and expand the reach of Novo Nordisk’s innovative therapies to a b…

Novo Nordisk India and Emcure Pharma announce partnership to launch Poviztra semaglutide injection 2.4 mg in India

Agreement covers distribution and marketing of Poviztra for weight management across expanded pharmacy networks and regions in India Novo Nordisk India and Emcure Pharma announced a strategic partnership to launch Poviztra, semaglutide injection 2.4 mg, in India. The collaboration will focus on distribution and marketing of semaglutide for weight loss through pharmacies, including regions not currently covered by Novo Nordisk India. Wegovy (sema…

Novo Nordisk partners Emcure Pharma for weight loss medicine Poviztra in India

New Delhi: Novo Nordisk India and Emcure Pharma on Monday announced a partnership to launch the weight-loss medicine Poviztra, semaglutide injection 2.4 mg, as a second brand of Wegovy in India. Wegovy (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity, as an adjunct to a reduced…